The work presented here shows that bezlotoxumab can prevent systemic disease pathologies and symptoms during acute infection, in particular thymic and kidney injury, and changes in serum glucose, urea and IL-6, and is supported by results published by others.48,58 Bezlotoxumab may therefore be a suitable adjunct therapy for cases of severe primary CDI, and may prevent the onset of systemic disease complications that may worsen patient outcomes. Here, IL6 is linked to clostridium difficile infection.